The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Open accessAbstract
BACKGROUND: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial toxic effects, and the manufacture of the cells is complex. Natural killer (NK) cells that have been modified to express an anti-CD19 CAR have the potential to overcome these limitations. METHODS: CAR-NK cells per kilogram of body weight) after lymphodepleting chemotherapy. RESULTS: The administration of CAR-NK cells was not associated with the development of cytokine release syndrome, neurotoxicity, or graft-versus-host disease, and there was no increase in the levels of inflammatory cytokines, including interleukin-6, over baseline. The maximum tolerated dose was not reached. Of the 11 patients who were treated, 8 (73%) had a response; of these patients, 7 (4 with lymphoma and 3 with CLL) had a complete remission, and 1 had remission of the Richter's transformation component but had persistent CLL. Responses were rapid and seen within 30 days after infusion at all dose levels. The infused CAR-NK cells expanded and persisted at low levels for at least 12 months. CONCLUSIONS: Among 11 patients with relapsed or refractory CD19-positive cancers, a majority had a response to treatment with CAR-NK cells without the development of major toxic effects. (Funded by the M.D. Anderson Cancer Center CLL and Lymphoma Moonshot and the National Institutes of Health; ClinicalTrials.gov number, NCT03056339.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The trial in adults with chronic lymphocytic leukemia demonstrated that CAR-NK targeting CD19 are safe and effective [143].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [143]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, the results from studies on targets other than CD19 in CAR-NK have been less than satisfactory, including both in vivo studies and clinical research.”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [143]
Experimental — accuracy not yet measuredIn the citing paper
“In a recent study of NK-cell CAR therapy, there were no reported cases of cytokine storm or even elevated interleukin-6 levels,60”
From Cytokine storm (2020) · cites this paper as [60]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationTisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Self-citationChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Miller, J. S., Soignier, Y., Panoskaltsis‐Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D. H., Le, C. T., DeFor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,894
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V. G., Landsburg, D. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,891
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Up on the tightrope: natural killer cell activation and inhibition
Lanier, L. L. (2008) · Nature Immunology · doi:10.1038/ni1581 · Cited by 1,656
Hallek, M., Cheson, B., Catovsky, D., Caligaris-cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M., Montserrat, E., Chiorazzi, N., et al. (2018) · Blood · doi:10.1182/blood-2017-09-806398 · Cited by 1,629
Self-citationCAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A., & Sadelain, M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0041-7 · Cited by 1,272
Liu, E., Tong, Y., Dotti, G., Shaim, H., Savoldo, B., Mukherjee, M., Orange, J. S., Wan, X., Lu, X. Y., Reynolds, A., et al. (2017) · Leukemia · doi:10.1038/leu.2017.226 · Cited by 843
Self-citationTurtle, C. J., Hay, K. A., Hanafi, L., Li, D., Cherian, S., Chen, X., Wood, B. L., Lozanski, A., Byrd, J. C., Heimfeld, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.8519 · Cited by 664
Rubnitz, J. E., Inaba, H., Ribeiro, R. C., Pounds, S., Rooney, B., Bell, T., Pui, C.-H., & Leung, W. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.4590 · Cited by 649
Hoyos, V., Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J. F., Heslop, H., Rooney, C. M., Brenner, M. K., & Dotti, G. (2010) · Leukemia · doi:10.1038/leu.2010.75 · Cited by 572
Dose‐Finding Based on Efficacy–Toxicity Trade‐Offs
Thall, P. F., & Cook, J. D. (2004) · Biometrics · doi:10.1111/j.0006-341x.2004.00218.x · Cited by 525
Self-citationEngineering Natural Killer Cells for Cancer Immunotherapy
Rezvani, K., Rouce, R. H., Liu, E., & Shpall, E. J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.06.012 · Cited by 459
Self-citationTagaya, Y., Bamford, R. N., DeFilippis, A. P., & Waldmann, T. A. (1996) · Immunity · doi:10.1016/s1074-7613(00)80246-0 · Cited by 440
Natural Killer Cells and Cancer
Wu, J., & Lanier, L. L. (2003) · Advances in cancer research · doi:10.1016/s0065-230x(03)90004-2 · Cited by 435
Olson, J. A., Leveson-Gower, D. B., Gill, S. I., Baker, J. B., Beilhack, A., & Negrin, R. S. (2010) · Blood · doi:10.1182/blood-2009-05-222190 · Cited by 387
Kataoka, T., Shinohara, N., Takayama, H., Takaku, K., Kondo, S., Yonehara, S., & Nagai, K. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.10.3678 · Cited by 377
Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect
Felices, M., Lenvik, A. J., McElmurry, R. T., Chu, S., Hinderlie, P., Bendzick, L. E., Geller, M. A., Tolar, J., Blazar, B. R., & Miller, J. S. (2018) · JCI Insight · doi:10.1172/jci.insight.96219 · Cited by 287
Lin, J. K., Muffly, L. S., Spinner, M. A., Barnes, J. I., Owens, D. K., & Goldhaber‐Fiebert, J. D. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02079 · Cited by 242
Shah, N. D., Li, L., McCarty, J. M., Kaur, I., Yvon, E. S., Shaim, H., Müftüoğlu, M., Liu, E., Orlowski, R. Z., Cooper, L. J. N., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14570 · Cited by 218
Self-citationAllogeneic BK Virus–Specific T Cells for Progressive Multifocal Leukoencephalopathy
Müftüoğlu, M., Olson, A. L., Marin, D., Ahmed, S., Mulanovich, V. E., Tummala, S., Chi, T., Ferrajoli, A., Kaur, I., Li, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801540 · Cited by 176
Self-citationNK cell alloreactivity and allogeneic hematopoietic stem cell transplantation
Ruggeri, L., Mancusi, A., Burchielli, E., Capanni, M., Carotti, A., Aloisi, T., Aversa, F., Martelli, M. F., & Velardi, A. (2007) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.06.029 · Cited by 159
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W. G., Locke, F. L., Lin, Y., Jain, N., Daver, N. G., Gulbis, A. M., Adkins, S., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.20 · Cited by 141
Self-citationToxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
Teachey, D. T., Bishop, M. R., Maloney, D. G., & Grupp, S. A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.19 · Cited by 115
Thall, P. F., Cook, J. D., & Estey, E. H. (2006) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400600860394 · Cited by 66
Self-citationCan we make a better match or mismatch with KIR genotyping?
Mehta, R. S., & Rezvani, K. (2016) · Hematology · doi:10.1182/asheducation-2016.1.106 · Cited by 38
Self-citationEffective sample size for computing prior hyperparameters in Bayesian phase I–II dose-finding
Thall, P. F., Herrick, R. C., Nguyen, H. Q., Venier, J. J., & Norris, J. C. (2014) · Clinical Trials · doi:10.1177/1740774514547397 · Cited by 31
Self-citationTisagenlecleucel in Diffuse Large B-Cell Lymphoma
Geoffrion, D., & Whittaker, H. T. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1901464 · Cited by 27
Paying for CAR-T Therapy Amidst Limited Health System Resources
Campbell, J. D., & Whittington, M. D. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01113 · Cited by 11
Flagged first, then by citations
Cited by
Sorted by citations
Fajgenbaum, D. C., & June, C. H. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2026131 · Cited by 3,196
Exploring the NK cell platform for cancer immunotherapy
Myers, J. A., & Miller, J. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,320
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
Morris, E. C., Neelapu, S. S., Giavridis, T., & Sadelain, M. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00547-6 · Cited by 1,187
Self-citationCancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636568 · Cited by 1,077
Natural killer cells in cancer biology and therapy
Wu, S.-Y., Fu, T., Jiang, Y.-Z., & Shao, Z.-M. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01238-x · Cited by 863
Metadata
- Authors
- Liu, E., Marin, D., Banerjee, P., Macapinlac, H. A., Thompson, P., Basar, R., Nassif Kerbauy, L., Overman, B., Thall, P., Kaplan, M., Nandivada, V., Kaur, I., Nunez Cortes, A., Cao, K., Daher, M., Hosing, C., Cohen, E. N., Kebriaei, P., Mehta, R., Neelapu, S., Nieto, Y., Wang, M., Wierda, W., Keating, M., Champlin, R., Shpall, E. J., & Rezvani, K.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- From the Departments of Stem Cell Transplantation and Cellular Therapy (E.L., D.M., P.B., R.B., L.N.K., B.O., M. Kaplan, V.N., I.K., A.N.C., M.D., C.H., P.K., R.M., Y.N., R.C., E.J.S., K.R.), Nuclear Medicine (H.A.M.), Leukemia (P. Thompson, W.W., M. Keating), Biostatistics (P. Thall), Laboratory Medicine (K.C.), Hematopathology (E.N.C.), and Lymphoma and Myeloma (S.N., M.W.), University of Texas M.D. Anderson Cancer Center, Houston.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-06
- Volume
- 382
- Issue
- 6
- Pages
- 545-553
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7101242
- OpenAlex
- W3004611567
- Cited by
- 2,217
- References
- 37
- Citations by year
- 2026: 282 · 2025: 337 · 2024: 332 · 2023: 323 · 2022: 353 · 2021: 379 · 2020: 205
- FWCI
- 113.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- M.D. Anderson Cancer Center CLL and lymphoma Moonshot Grants
- National Institutes of Health (1 R01 CA211044-01, 5P01CA148600-03, CA016672, P50CA100632-16)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CAR-NK cells, chimeric antigen receptor, natural killer cells, anti-CD19, relapsed or refractory B-cell lymphoma, chronic lymphocytic leukemia, Richter transformation, lymphodepleting chemotherapy, cytokine release syndrome, neurotoxicity, graft-versus-host disease, interleukin-6, CAR T-cell toxicity
- MeSH terms
- Receptors, Chimeric Antigen, Aged, Female, Fetal Blood, Genetic Vectors, Humans, Killer Cells, Natural, Lymphoma, Non-Hodgkin, Male, Middle Aged, Remission Induction, Retroviridae, Leukemia, Lymphocytic, Chronic, B-Cell, Antigens, CD19, Transplantation Conditioning, Allografts, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
